Jeanne A. Jordan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeanne A. Jordan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Allyson R. Butchko
3 shared publicationsMary Beth Durso
3 shared publicationsBeverly S. Brozanski
1 shared publicationCarole C. Wegner
University of Pittsburgh, Department of Pathology, Pittsburgh, PA, USA
1 shared publicationJudith G. Jones
1 shared publication
Latest Publications
- 1 July 2006
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 8 (3) , 357-363
Evaluating the Near-Term Infant for Early Onset Sepsis
- 1 July 2006
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 8 (3) , 357-363
Evaluating the Near-Term Infant for Early Onset Sepsis
- 1 November 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (5) , 575-581
Real-Time Polymerase Chain Reaction for Detecting Bacterial DNA Directly from Blood of Neonates Being Evaluated for Sepsis
- 1 November 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (5) , 575-581
Real-Time Polymerase Chain Reaction for Detecting Bacterial DNA Directly from Blood of Neonates Being Evaluated for Sepsis
- 1 February 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (1) , 105-110
Use of Pyrosequencing of 16S rRNA Fragments to Differentiate between Bacteria Responsible for Neonatal Sepsis
- 1 February 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (1) , 105-110
Use of Pyrosequencing of 16S rRNA Fragments to Differentiate between Bacteria Responsible for Neonatal Sepsis
- 1 July 2004
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (7) , 3191-3195
Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women
A split-sample study was conducted to evaluate the performances of three enzyme immunoassays (EIAs) utilizing one or more conformational antigens to detect human parvovirus B19 (B19V)-specific immunoglobulin M (IgM) or IgG in the sera of 198 pregnant women. We compared EIAs available from Biotrin International, Inc. (Dublin, Ireland), Medac Diagnostika (Wedel, Germany), and Mikrogen (Martinsried, Germany). Specimens with discordant results were analyzed further using an immunofluorescence assay (Biotrin). Equivocal data accounted for close to half of all the discrepant results for both IgM and IgG, with 7 of 15 discrepant results from the Medac and Mikrogen kits involving equivocal data and the Biotrin kit giving a single equivocal result. For each specimen, a consensus was established from the four test results if agreement occurred among at least three of four results. Overall, the highest percentage of agreement with the consensus results was seen when Biotrin kits were used; 194 (100%) of 194 and 194 (99.5%) of 195 results for IgM and IgG, respectively, agreed with the consensus results. When Medac kits were used, 189 (97.4%) of 194 and 191 (97.9%) of 195 results for IgM and IgG, respectively, agreed with the consensus, and when Mikrogen kits were used, 179 (92.3%) of 194 and 193 (99%) of 195 results for IgM and IgG, respectively, agreed with the consensus. Given the consensus results, the Medac EIA appeared to generate presumed false-positive results for IgM and the Mikrogen EIA appeared to generate presumed false-positive results for IgG and IgM. In summary, the Biotrin EIAs produced far fewer equivocal results than the other assays and results of the Biotrin EIAs agreed more often with the consensus results than did those of the other commercially available EIAs for detecting B19V-specific IgM and IgG antibodies.
- 1 July 2004
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (7) , 3191-3195
Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women
A split-sample study was conducted to evaluate the performances of three enzyme immunoassays (EIAs) utilizing one or more conformational antigens to detect human parvovirus B19 (B19V)-specific immunoglobulin M (IgM) or IgG in the sera of 198 pregnant women. We compared EIAs available from Biotrin International, Inc. (Dublin, Ireland), Medac Diagnostika (Wedel, Germany), and Mikrogen (Martinsried, Germany). Specimens with discordant results were analyzed further using an immunofluorescence assay (Biotrin). Equivocal data accounted for close to half of all the discrepant results for both IgM and IgG, with 7 of 15 discrepant results from the Medac and Mikrogen kits involving equivocal data and the Biotrin kit giving a single equivocal result. For each specimen, a consensus was established from the four test results if agreement occurred among at least three of four results. Overall, the highest percentage of agreement with the consensus results was seen when Biotrin kits were used; 194 (100%) of 194 and 194 (99.5%) of 195 results for IgM and IgG, respectively, agreed with the consensus results. When Medac kits were used, 189 (97.4%) of 194 and 191 (97.9%) of 195 results for IgM and IgG, respectively, agreed with the consensus, and when Mikrogen kits were used, 179 (92.3%) of 194 and 193 (99%) of 195 results for IgM and IgG, respectively, agreed with the consensus. Given the consensus results, the Medac EIA appeared to generate presumed false-positive results for IgM and the Mikrogen EIA appeared to generate presumed false-positive results for IgG and IgM. In summary, the Biotrin EIAs produced far fewer equivocal results than the other assays and results of the Biotrin EIAs agreed more often with the consensus results than did those of the other commercially available EIAs for detecting B19V-specific IgM and IgG antibodies.
- Open Access
- 26 January 2004
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 12 (2) , 69-78
Human Parvovirus B19 VP2 Empty Capsids Bind to Human Villous Trophoblast Cells in vitro Via the Globoside Receptor
Background: Pregnant women acutely infected with human parvovirus B19 (B19) may transmit the virus to the developing fetus. The mechanism whereby the virus interacts with the placenta is unknown. It is known that globoside receptor is required for successful infection of the target cells, which are the highly undifferentiated, actively dividing colony and burst‐form units of the erythroid series. Globoside is present on trophoblast cells which have intimate contact with maternal blood, and may therefore serve as a potential route for B19 transmission into the fetal compartment.Objectives: The purpose of this study was to determine whether B19 VP2 capsids could bind to villous trophoblast cells in vitro and whether globoside was involved.Methods: Binding of B19 VP2 empty capsid to first‐trimester villous trophoblast cells was assessed by multiple approaches, including ICC using either biotinylated B19 VP2 empty capsid or unlabeled B19 VP2 empty capsid. Quantification of viral binding involved I125 ‐labeled B19 VP2 empty capsid. Competition studies included excess unlabeled empty capsids or pretreatment with globoside‐specific IgM antibody.Results: Linear binding of B19 VP2 capsid to purified villous trophoblast cells in vitro was clearly demonstrated (R2 = 0.9524). Competition studies revealed specificity of I125 ‐labeled B19 VP2 capsid binding to villous trophoblast cells when pretreatment with either 60‐fold excess unlabeled B19 capsid or globoside‐specific IgM antibody took place. The results illustrated B19′s ability to bind in a specific manner to globoside‐containing villous trophoblast cells.Conclusion: We speculate that the globoside present on trophoblast cells may play a role in viral binding in vivo, which may facilitate B19 transmission across the maternal–fetal interface.
- 26 January 2004
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 12 (2) , 69-78
Open AccessHuman Parvovirus B19 VP2 Empty Capsids Bind to Human Villous Trophoblast Cells in vitro Via the Globoside Receptor
Background: Pregnant women acutely infected with human parvovirus B19 (B19) may transmit the virus to the developing fetus. The mechanism whereby the virus interacts with the placenta is unknown. It is known that globoside receptor is required for successful infection of the target cells, which are the highly undifferentiated, actively dividing colony and burst‐form units of the erythroid series. Globoside is present on trophoblast cells which have intimate contact with maternal blood, and may therefore serve as a potential route for B19 transmission into the fetal compartment.Objectives: The purpose of this study was to determine whether B19 VP2 capsids could bind to villous trophoblast cells in vitro and whether globoside was involved.Methods: Binding of B19 VP2 empty capsid to first‐trimester villous trophoblast cells was assessed by multiple approaches, including ICC using either biotinylated B19 VP2 empty capsid or unlabeled B19 VP2 empty capsid. Quantification of viral binding involved I125 ‐labeled B19 VP2 empty capsid. Competition studies included excess unlabeled empty capsids or pretreatment with globoside‐specific IgM antibody.Results: Linear binding of B19 VP2 capsid to purified villous trophoblast cells in vitro was clearly demonstrated (R2 = 0.9524). Competition studies revealed specificity of I125 ‐labeled B19 VP2 capsid binding to villous trophoblast cells when pretreatment with either 60‐fold excess unlabeled B19 capsid or globoside‐specific IgM antibody took place. The results illustrated B19′s ability to bind in a specific manner to globoside‐containing villous trophoblast cells.Conclusion: We speculate that the globoside present on trophoblast cells may play a role in viral binding in vivo, which may facilitate B19 transmission across the maternal–fetal interface.